Fordyce Marshall sold $2.0M of VERA

Vera Therapeutics (VERA) stock rose 7% after FDA approval of Trutakna for treating IgA Nephropathy. The drug showed a 46% reduction in proteinuria in trials. CEO Marshall Fordyce highlighted its potential to address unmet medical needs. VERA is up 90% over 12 months despite a 14% year-to-date decline.

Vera Therapeutics, Inc. (VERA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Vera Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results • TRUTAKNA™ granted accelerated approval by U.S. Food and Drug Administration (FDA) in adult patients with primary IgA nephropathy (IgAN) at risk for disease progression. • A

Vera Therapeutics (NASDAQ:VERA) shares rose about 9% after the FDA approved Trutakna under the accelerated approval pathway for IgA nephropathy. Interim Phase 3 ORIGIN 3 data for 203 participants showed statistically significant proteinuria reductions vs placebo (42% at 36 weeks; 46% UPCR reduction from baseline). Confirmatory benefit depends on ongoing ORIGIN 3 results expected in Q3 2026.

Vera Therapeutics (Nasdaq: VERA) said the FDA granted accelerated approval for TRUTAKNA (atacicept-vymj) to reduce proteinuria in adults with primary IgA nephropathy at risk for progression. In ORIGIN 3 interim analysis, TRUTAKNA cut UPCR 46% vs baseline and 42% vs placebo (statistically significant). Safety in 428 patients included infections (32% vs 28%) and injection reactions (30% vs 5%); long-term kidney benefit pending Q3 2026.

Vera Therapeutics (Nasdaq: VERA) said the FDA granted accelerated approval to TRUTAKNA (atacicept-vymj) for adults with primary IgA nephropathy at risk of progression. In ORIGIN 3 interim analysis, TRUTAKNA reduced proteinuria (UPCR) 46% vs baseline and 42% vs placebo at 36 weeks (p<0.0001). Common AEs were infections and local reactions; long-term kidney benefit not yet established.

Vera Therapeutics’ (NASDAQ:VERA) shares rose about 1% to $41.60 Monday after gaining ~30% over the past month. The company is awaiting an FDA decision due July 7 on accelerated approval of atacicept for IgA nephropathy, supported by ORIGIN 3 interim data showing proteinuria reductions vs placebo. eGFR results are expected in Q3 2026.